Odonate Therapeutics, Inc. functions as a pharmaceutical enterprise, dedicating its efforts to the creation of innovative therapeutic agents for cancer treatment. A prominent compound within its development pipeline is tesetaxel, an orally administered chemotherapy drug. This agent is currently advancing through Phase III clinical trials, specifically under investigation for its application in individuals with metastatic breast cancer. Established in 2013, the company's operations are headquartered in New York, New York.


Net sales
Gross margin
Net income